Phil Nadeau
Stock Analyst at TD Cowen
(4.50)
# 1,091
Out of 4,651 analysts
784
Total ratings
50.5%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintained: Buy | n/a | $10.86 | - | 22 | Aug 12, 2026 | |
| ANNX Annexon | Maintained: Buy | n/a | $5.29 | - | 19 | Aug 12, 2026 | |
| IPSC Century Therapeutics | Maintained: Buy | n/a | $1.92 | - | 5 | Aug 12, 2026 | |
| NKTX Nkarta | Maintained: Buy | n/a | $2.33 | - | 2 | Aug 10, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $16.47 | - | 20 | Aug 10, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $120 | $67.34 | +78.20% | 84 | Aug 7, 2026 | |
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.27 | - | 43 | Aug 6, 2026 | |
| EDIT Editas Medicine | Maintained: Buy | n/a | $2.82 | - | 28 | Aug 5, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | n/a | $9.24 | - | 21 | Aug 5, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | n/a | $58.82 | - | 18 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $525 → $550 | $505.75 | +8.75% | 87 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.84 | - | 22 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $115.48 | +12.57% | 37 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $220 | $152.72 | +44.05% | 57 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $215 → $225 | $209.83 | +7.23% | 55 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.75 | - | 15 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.69 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.96 | - | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $17.14 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $8.09 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $27.53 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.73 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.28 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $75 | $138.36 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.15 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.05 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.47 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $803.48 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.36 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $16 | $0.000001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $415.21 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.32 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $499.73 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $18.10 | n/a | 1 | Aug 7, 2015 |
Kura Oncology
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $10.86
Upside: -
Annexon
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $5.29
Upside: -
Century Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $1.92
Upside: -
Nkarta
Aug 10, 2026
Maintained: Buy
Price Target: n/a
Current: $2.33
Upside: -
MoonLake Immunotherapeutics
Aug 10, 2026
Maintained: Buy
Price Target: n/a
Current: $16.47
Upside: -
BioMarin Pharmaceutical
Aug 7, 2026
Maintained: Buy
Price Target: $120
Current: $67.34
Upside: +78.20%
Voyager Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $3.27
Upside: -
Editas Medicine
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $2.82
Upside: -
Vir Biotechnology
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $9.24
Upside: -
Enliven Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $58.82
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $525 → $550
Current: $505.75
Upside: +8.75%
Aug 4, 2026
Maintained: Buy
Price Target: n/a
Current: $19.84
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $130
Current: $115.48
Upside: +12.57%
Jul 31, 2026
Rated: Buy
Price Target: $200 → $220
Current: $152.72
Upside: +44.05%
Jul 30, 2026
Rated: Buy
Price Target: $215 → $225
Current: $209.83
Upside: +7.23%
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $2.75
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $7.69
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $23.96
Upside: -
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $17.14
Upside: -
Mar 9, 2025
Maintained: Buy
Price Target: n/a
Current: $8.09
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: n/a
Current: $27.53
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $4.73
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $13.28
Upside: n/a
Feb 4, 2021
Maintained: Buy
Price Target: $80 → $75
Current: $138.36
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $15.15
Upside: n/a
Aug 7, 2019
Maintained: Buy
Price Target: n/a
Current: $2.05
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $3.47
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $803.48
Upside: n/a
Jan 17, 2019
Maintained: Hold
Price Target: n/a
Current: $4.36
Upside: n/a
Nov 2, 2018
Maintained: Buy
Price Target: $2 → $16
Current: $0.000001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $415.21
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $2.32
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $499.73
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $18.10
Upside: n/a